Salud
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
ENIn English
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
STAT News1 min de lecturaOriginal en EN
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
Leer artículo completo en STAT News
